Surrozen Dividend

Dividend criteria checks 0/6

Surrozen does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.8%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$11.75
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SRZN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRZN's dividend payments have been increasing.

Dividend Yield vs Market

Surrozen Dividend Yield vs Market

How does SRZN dividend yield compare to the market?
Segment	Dividend Yield
Company (SRZN)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.6%
Industry Average (Biotechs)	2.8%
Analyst forecast in 3 Years (SRZN)	0%

Notable Dividend: Unable to evaluate SRZN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRZN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SRZN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SRZN has not reported any payouts.

Surrozen Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Surrozen, Inc., Annual General Meeting, Jun 05, 2024

Surrozen, Inc. announced delayed annual 10-K filing

Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis

Surrozen, Inc. announced that it expects to receive $17.549999 million in funding from The Column Group, LLC, Ra Capital Management, Inc.

Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer

Surrozen, Inc. Provides Corporate Update on Clinical Programs

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis

New minor risk - Share price stability

Surrozen, Inc. Announces Management Changes

Nasdaq Grants Surrozen Additional 180 Calendar Day Period to Regain Compliance with the Minimum Bid Price Per Share Requirement for Continued Listing

Will Surrozen (NASDAQ:SRZN) Spend Its Cash Wisely?

Here's Why Surrozen (NASDAQ:SRZN) Must Use Its Cash Wisely

Surrozen Receives A Written Notice from Nasdaq Regarding Minimum Bid Requirement

Surrozen, Inc. (NasdaqCM:SRZN) announces an Equity Buyback for 1,310,496 shares, for $2.7 million.

Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopathies, Including Diabetic Retinopathy and Diabetic Macular Edema

Price target decreased to US$12.50

Surrozen stock rises ~13% premarket on licensing deal with Boehringer Ingelheim

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of Szn-413 in Preclinical Models of Diabetic Retinopathy

Surrozen GAAP EPS of -$0.40 beats by $0.06

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Price target increased to US$19.50

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy At the Association for Research in Vision and Ophthalmology Annual Meeting

Surrozen CEO Craig Parker - Biotechs Can Never Be Too Well Capitalized (Video)

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies